HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug
about
The β-Lactamase Assay: Harnessing a FRET Biosensor to Analyse Viral Fusion MechanismsMaraviroc: a review of its use in HIV infection and beyondCharacterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.Controlling the HIV/AIDS epidemic: current status and global challengesA single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsAstrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material.Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
P2860
Q26747003-0F3895A3-75F0-4F67-B034-81F43C391D46Q26778504-61C33E97-9CA2-4182-888C-62CD163B628EQ30378764-95909468-4C2D-4E7E-A193-9A3B33DEC81FQ30420558-EAE0FBDE-FD68-4057-9976-B38F0353F59FQ30654651-4A89FF54-4686-4D69-8F48-680F51B7F219Q34310045-7A08F996-D68F-4D2D-BB7F-9B4F426A2CB3Q35071940-6CE98CF1-9B11-4FD4-960A-77F7B975D44DQ35867443-43D8C8D1-D76E-4663-97D9-96BB4CE08B51Q36086642-557C8CE0-C678-4430-B053-DEF94BBFB5F3Q36827946-E441C3B5-2E7E-406B-86D1-A75517FF8BF7Q37651758-AC7B9188-2C41-4EA8-983F-A09EBD31FAE4Q37703084-03230467-3A3B-45B4-B834-09C683C764A7Q38076139-734054FD-2C79-4A5D-8D51-1A4658FF3BFFQ38079744-FE966397-B177-4780-9754-0980B47A5444Q38196457-26A3C8C6-F140-431D-AE71-2560FA391743Q38822845-B5FB5B4E-93D6-4EB9-96A1-D780697CF991Q39361526-9CD5DA94-8380-4BF8-83D4-0C03045D0A82Q41808324-F875748E-8A58-46F9-8C0E-534F3749D97C
P2860
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
HIV-1 clinical isolates resist ...... rected in the presence of drug
@ast
HIV-1 clinical isolates resist ...... rected in the presence of drug
@en
type
label
HIV-1 clinical isolates resist ...... rected in the presence of drug
@ast
HIV-1 clinical isolates resist ...... rected in the presence of drug
@en
prefLabel
HIV-1 clinical isolates resist ...... rected in the presence of drug
@ast
HIV-1 clinical isolates resist ...... rected in the presence of drug
@en
P2093
P2860
P356
P1433
P1476
HIV-1 clinical isolates resist ...... rected in the presence of drug
@en
P2093
Athe M N Tsibris
Daniel R Kuritzkes
Eoin Coakley
Jakapat Vanichanan
Opass Putcharoen
Roy M Gulick
Sun Hee Lee
Timothy J Henrich
Wayne Greaves
P2860
P304
P356
10.1128/JVI.06421-11
P407
P577
2011-11-16T00:00:00Z